A new low-dose monophasic combination oral contraceptive (Alesse™) with levonorgestrel 100 μg and ethinyl estradiol 20 μg

Archer, David F.; Maheux, Rodolphe; DelConte, Anthony; O’Brien, Francis B.

doi:10.1016/s0010-7824(97)00024-3

Cited by 56 publications

(19 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…(23) Dieben et al 2002, (19) and Archer et al 2002. (24) In the present study treatment related adverse events with CCVR (nuvaring) were headache-3.8%, vaginitis-2.5%, leucorrea-4%, nausea-2.8% and device related events-8% which included coital problems, foreign body sensation and spontaneous expulsion.…”

Section: Resultsmentioning

confidence: 47%

To Study the Acceptability and Efficacy of Combined Contraceptive Vaginal Ring Amidst Indian Women

Dam¹,

Paul²,

Banerjee³

et al. 2015

jemds

View full text Add to dashboard Cite

OBJECTIVES:To study the efficacy, and acceptability and reasons for discontinuity of CCVRs in Indian women along with cycle control, safety aspects, local and systemic adverse effects, chances of spontaneous expulsion and partner compliance. METHODS: This interventional longitudinal study included 45 married women aged between 18-45 years seeking reversible means of contraception but with no history of usage of any form of hormonal contraceptives in the previous 6 months. The outcome variables were measured in terms of contraceptive efficacy, cycle regularity, systemic effects on blood pressure, liver function, body weight, lipid parameters and blood sugar along with local effect on cervix and vagina. Patient compliance, acceptability and spouse compliance was also measured by questionnaires. RESULTS: In this study there were no unwanted pregnancies in women amongst 117 exposed cycles. The incidence of intended bleeding pattern was 95%, the effect of CCVR on liver function, blood pressure, etc. was not clinically relevant. It was not associated with an increased risk of cervical or vaginal abnormalities, 96% women were satisfied with the ring usage and 97% would recommend it to others, 70% of women and 82% of their partners never/ rarely felt the ring during intercourse. CONCLUSION: From the present study, it can be concluded that CCVR is an effective contraceptive with good cycle control, minimal systemic or local adverse effects along with low incidence of spontaneous expulsion and higher level of user and partner acceptability.

show abstract

Section: Resultsmentioning

confidence: 47%

To Study the Acceptability and Efficacy of Combined Contraceptive Vaginal Ring Amidst Indian Women

Dam¹,

Paul²,

Banerjee³

et al. 2015

jemds

View full text Add to dashboard Cite

show abstract

“…There were no serious adverse events attributed to the trial medication. The adverse events that affected our patients were of the same type as the widely accepted complaints characterizing the use of OCs; due to the smaller number of participants, the frequency of side effects in this study was higher than previously reported 21,22 . The safety profile of EE/CMA is most likely related to its almost complete absence of mineralocorticoid and anti-mineralocorticoid effects, and its lack of interference with hepatic metabolism 9 .…”

Section: Discussion a N D C O N C L U S I O Nmentioning

confidence: 46%

Contraceptive efficacy and safety of a low-dose oral contraceptive, (0.03 mg ethinyl oestradiol and 2 mg chlormadinone acetate) Belara®, over three medication cycles

Spona

Binder

Höschen

et al. 2008

The European Journal of Contraception & Reproductive Health

View full text Add to dashboard Cite

show abstract

“…Outro estudo 21 com 783 mulheres, a taxa de continuação aos 6 meses de início do uso foi de 88 e 86%, respectivamente, para ACO monofásico ambos com 30 μg de EE e 150 μg de desogestrel (DSG) ou 75 μg de GSD. Dois estudos realizados nos Estados Unidos mostraram taxas de continuação aos 6 meses de 53,6% entre 1.477 mulheres e 7.870 ciclos de avaliação de um ACO com levonorgestrel (LNG) 100 μg e EE 20 μg 22 ; o outro estudo 23 com 1.716 mulheres com menos de 25 anos de idade avaliadas em clínicas do setor públi-co mostrou somente 43% de taxa de continuação com o uso de um ACO. Estes autores mostraram também que as descontinuações ocorreram por razões não relacionadas com eventos adversos e de fato estes não estiveram presentes.…”

Section: Resultsunclassified

Fatores associados à descontinuação do uso de anticoncepcionais orais combinados

Bahamondes¹,

Pinho²,

Melo³

et al. 2011

Rev. Bras. Ginecol. Obstet.

View full text Add to dashboard Cite

Fatores associados à descontinuação do uso de anticoncepcionais orais combinados Associated factors with discontinuation use of combined oral contraceptives Artigo originalResumo OBJETIVO: Avaliar as razões para descontinuar diversos anticoncepcionais orais combinados entre mulheres brasileiras iniciantes do método, residentes em áreas urbanas. MÉTODOS: Estudo de corte transversal com 400 ginecologistas do Brasil, registrados na Federação Brasileira de Ginecologia e Obstetrícia. Cada médico entrevistou 10 mulheres não grávidas, não lactantes, não em amenorreia, com idades entre 18 e 39 anos que consultavam solicitando anticoncepcional oral combinado (ACO), com um questionário no início de uso e aos 6 meses posteriores. O questionário incluiu dados sociodemográficos, tipo de ACO escolhido ou prescrito e razões para descontinuação, caso ocorresse durante o seguimento. A estratégia de seleção permitiu a inclusão de mulheres de diferentes estratos socioeconômicos, mas somente atendidas em consultórios privados ou de convênios. O tamanho da amostra foi estimado em 1.427 mulheres. RESULTADOS: Foram obtidas 3.465 entrevistas na primeira visita e 1.699 aos 6 meses posteriores. As mulheres tinham predominantemente entre 20 e 29 anos, 57,3% eram solteiras e em proporção quase igual de 45% tinham ensino médio ou superior. A maioria (60,7%) era nuligestas e dentre as que tinham usado algum método contraceptivo anteriormente, 71,8% tinham utilizado ACO. Entre os ACO mais prescritos ou escolhidos, o mais prevalente foram os monofásicos com etinilestradiol (20 µg) e no tocante ao progestágeno, o mais prevalente foi com gestodeno (36,5%), seguido por ACO com drosperinona (22,0%). Aos 6 meses, 63,5% continuavam em uso do ACO. Dentre as que descontinuaram o uso, as principais razões dadas foram: desejo de engravidar (36,5%) e efeitos colaterais (57,3%) como cefaléia (37,6%), aumento de peso (16,6%) e sangramento irregular (23,6%). CONCLUSÕES: A taxa de continuação do uso de ACO foi baixa aos seis meses e este estudo pode contribuir para que os médicos orientem melhor suas pacientes iniciantes no uso de ACO sobre os eventos adversos esperados que são mínimos e temporários e sobre os benefícios não contraceptivos dos ACO.Abstract PURPOSE: Due to the scarce information available in Brazil in relation to the number of women who initiated the use of combined oral contraceptives and prematurely discontinued, the objective was to assess the reasons for discontinuation of the use of several combined oral contraceptives among Brazilian women living in urban areas. METHODS: A crosssectional study with 400 gynecologists registered withy the Brazilian Federation of Obstetricians and Gynecologists. Each physician interviewed 10 non-pregnant, not breastfeeding, not amenorrheic women aged 18 to 39 years who consulted requesting combined oral contraceptive (COC) with a questionnaire at the beginning of use and at six months later. The questionnaire included sociodemographic data, type of COC chosen or prescribed and reasons for discontinuation w...

show abstract

A new low-dose monophasic combination oral contraceptive (Alesse™) with levonorgestrel 100 μg and ethinyl estradiol 20 μg

Cited by 56 publications

References 6 publications

To Study the Acceptability and Efficacy of Combined Contraceptive Vaginal Ring Amidst Indian Women

To Study the Acceptability and Efficacy of Combined Contraceptive Vaginal Ring Amidst Indian Women

Contraceptive efficacy and safety of a low-dose oral contraceptive, (0.03 mg ethinyl oestradiol and 2 mg chlormadinone acetate) Belara®, over three medication cycles

Fatores associados à descontinuação do uso de anticoncepcionais orais combinados

Contact Info

Product

Resources

About